You are here: Industry Insights > Alnylam

News List

Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues firstwordpharma
July 30, 2021
Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY) announced today a license and collaboration agreement to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver.
Alnylam's RNAi therapeutic Oxlumo gets EU green light pharmatimes
November 23, 2020
Alnylam Pharmaceuticals has scored an approval from the European Commission for its RNAi therapeutic Oxlumo, for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
Alnylam Partners with Sharp contractpharma
September 21, 2020
Signs an agreement for the packaging of Alnylam’s approved RNAi therapeutic in European markets.
Vir Biotechnology and Alnylam expand alliance for Covid-19 drugs pharmaceutical-technology
April 06, 2020
Vir Biotechnology and Alnylam Pharmaceuticals have expanded their multi-target infectious diseases alliance to include up to three targets for SARS-CoV-2, the novel coronavirus that causes Covid-19.
EC approves Alnylam’s Givlaari for acute hepatic porphyria pharmaceutical-technology
March 05, 2020
The European Commission (EC) has approved Alnylam’s Givlaari (givosiran) for adults and adolescents with acute hepatic porphyria (AHP).
Alnylam initiates rolling submission of NDA for Lumasiran in primary Hyperoxaluria Type 1 pharmaceutical-business-review
January 15, 2020
Alnylam Pharmaceuticals has initiated a rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperox
Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1) firstwordpharma
January 11, 2020
Alnylam also announced that it has been granted a pediatric rare disease designation from the FDA for lumasiran for the treatment of PH1.
Lumasiran drug achieves primary and secondary endpoints in Phase III study europeanpharmaceuticalreview
December 23, 2019
Lumasiran, an investigational drug to treat primary hyperoxaluria type 1, has met its endpoints in clinical trials.
Alnylam recruits former Shire exec to replace departing CFO Soni fiercepharma
July 13, 2019
It’s been less than two years since former Shire CFO Jeff Poulton left the biopharma world, but he’s back—and he’s landed at Alnylam.
Sanofi concludes option phase of rare disease alliance with Alnylam pharmaceutical-technology
April 23, 2019
Sanofi concludes option phase of rare disease alliance with Alnylam.

Previous page 1 2 3 Next page